EFFECT OF CISPLATIN ON THIOACETAMIDE INDUCED HCC IN RATS
Yaseen Othman Hamed, Amal M. El Gayar, and Yousra M. El-Far
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Hepatocellular carcinoma (HCC) is widespread in many countries around the world and remains the third leading cause of cancer related death. Egypt has the highest prevalence of HCV in the world; where it causes more than 90 percent of HCC cases. Cisplatin (CP) is one of the chemotherapeutic medications widely used for treating patients with advanced liver cancer. In this study, Thioacetamide (TAA) was injected intraperitoneally twice weekly for 16 weeks to induce HCC in rats, after HCC establishment, rats were divided randomly into HCC control and CP- treated groups. In CP- treated groups, rats were received CP for 3 weeks. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were detected kinetically, as well as hepatic content of malondialdehyde (MDA) was determined spectrophotometrically. Our results showed that, CP treatment reduced TAA-induced elevation in ALT and AST activities as well as hepatic MDA content. Therefore, CP treatment successfully attenuated TAA induced HCC and its effect may be attributed to its antioxidant capability.